Study on Bladder and Sexual Function Change After Simple Hysterectomy
NCT ID: NCT01683890
Last Updated: 2017-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2012-09-30
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer
NCT01893333
Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
NCT01658930
Total Versus Subtotal Hysterectomy:a Randomised, Prospective Multicentre Study of the Effect on Urinary, Sexual and Bowel Function
NCT00750035
Impact of Hysterectomy on Quality of Life and Urethral Length
NCT03757975
The Pelvic Floor Function and Sexual Life of the Women After Different Type of Hysterectomy
NCT02841059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simple hysterectomy group
Patients will undergo simple hysterectomy due to benign uterine disease.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Uterine leiomyoma
2. Uterine adenomyosis
3. Endometrial hyperplasia
4. Cervical intraepithelial neoplasia (including carcinoma in situ, FIGO stage IA1 cancer)
5. Dysfunctional uterine bleeding
6. Other benign uterine disease requiring hysterectomy
Exclusion Criteria
* Patients who underwent incontinence surgery due to urinary incontinence
* Acute or chronic infectious disease of urinary tract
* Neurologic disease causing urinary abnormality
* Previous pelvic radiation therapy
* Patients who are undergoing incontinence surgery with hysterectomy
* Pregnant woman
20 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hee-Dong Chae
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hee-Dong Chae, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SBSFSH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.